| 中文名称 | (R)-4-(4-((4'-氯-4,4-二甲基-3,4,5,6-四氢-[1,1'-联苯]-2-基)甲基)哌嗪-1-基)-N-((4-((4-吗啉-1-(苯硫基)丁烷-2-基)氨基)-3-((三氟甲基)磺酰)苯基)磺酰)苯甲酰胺 |
|---|---|
| 英文名称 | Navitoclax (Synonyms: ABT-263; A-855071) |
| CAS号 | 923564-51-6 |
| 分子式 | C47H55ClF3N5O6S3 |
| 分子量 | 974.61 |
| 外观 | White to light yellow powder |
| 储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Navitoclax, also known as ABT-263, is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.
Tags: buy Navitoclax (ABT-263) | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | order Navitoclax (ABT-263) | Navitoclax (ABT-263) chemical structure | Navitoclax (ABT-263) in vivo | Navitoclax (ABT-263) in vitro | Navitoclax (ABT-263) formula | Navitoclax (ABT-263) molecular weight
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft